Next Article in Journal
Review of Polymer-Based Composites for Electromagnetic Shielding Application
Previous Article in Journal
Comparative Transcriptomic Analysis of the Metabolism of Betalains and Flavonoids in Red Amaranth Hypocotyl under Blue Light and Dark Conditions
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 15
10.3390/molecules28155626
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Molecules 2020, 25(13), 3031.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Neamatallah et al. Nano Ellagic Acid Counteracts Cisplatin-Induced Upregulation in OAT1 and OAT3: A Possible Nephroprotection Mechanism. Molecules 2020, 25, 3031

by
Thikryat Neamatallah
1,
Nagla El-Shitany
1,2,*,
Aymn Abbas
3,4,
Basma G. Eid
1,
Steve Harakeh
3,5,
Soad Ali
6 and
Shaker Mousa
5
1
Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
2
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta 31511, Egypt
3
Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia
4
Biotechnology Research Laboratories, Gastroenterology Surgery Center, Mansoura University, Mansoura 35511, Egypt
5
Yousef Abdullatif Jameel Chair of Prophetic Medicine Application, King Abdulaziz University, Jeddah 21589, Saudi Arabia
6
Anatomy Department of Cytology and Histology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia
*
Author to whom correspondence should be addressed.
Molecules 2023, 28(15), 5626; https://doi.org/10.3390/molecules28155626
Submission received: 12 November 2022 / Accepted: 29 January 2023 / Published: 25 July 2023
Browse Figures
Versions Notes

Error in Figure

In the original publication, there was a mistake in Figure 3 as published [1]. We observed that photo B was mistakenly presented in the cisplatin group. However, this photo was from the ellagic acid nano (2 mg/kg) group. So, we changed photo B with another photo from the cisplatin group. This doesn’t change the conclusion made. The corrected Figure 3 appears below.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Neamatallah, T.; El-Shitany, N.; Abbas, A.; Eid, B.G.; Harakeh, S.; Ali, S.; Mousa, S. Nano ellagic acid counteracts cisplatin-induced upregulation in OAT1 and OAT3: A possible nephroprotection mechanism. Molecules 2020, 25, 3031. [Google Scholar] [CrossRef] [PubMed]
Molecules 28 05626 g001a 550Molecules 28 05626 g001b 550
Figure 3. Impact of ellagic acid nanoformulation on kidney OAT3 immunoexpression examined in cisplatin-treated rats. (A): Control group; (B): Cisplatin group; (C): Ellagic acid nano (1 mg/kg); and (D): Ellagic acid nano (2 mg/kg). (E): Bar chart showing OAT3 immunoexpression (area %) in the different experimental groups. Results are given as mean ± SE (n = 6). * p ≤ 0.05 relative to the control group; # p ≤ 0.05 relative to cisplatin group; Ω p ≤ 0.05 relative to ellagic acid nano (1 mg/kg) group.
Figure 3. Impact of ellagic acid nanoformulation on kidney OAT3 immunoexpression examined in cisplatin-treated rats. (A): Control group; (B): Cisplatin group; (C): Ellagic acid nano (1 mg/kg); and (D): Ellagic acid nano (2 mg/kg). (E): Bar chart showing OAT3 immunoexpression (area %) in the different experimental groups. Results are given as mean ± SE (n = 6). * p ≤ 0.05 relative to the control group; # p ≤ 0.05 relative to cisplatin group; Ω p ≤ 0.05 relative to ellagic acid nano (1 mg/kg) group.
Molecules 28 05626 g001aMolecules 28 05626 g001b
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Neamatallah, T.; El-Shitany, N.; Abbas, A.; Eid, B.G.; Harakeh, S.; Ali, S.; Mousa, S. Correction: Neamatallah et al. Nano Ellagic Acid Counteracts Cisplatin-Induced Upregulation in OAT1 and OAT3: A Possible Nephroprotection Mechanism. Molecules 2020, 25, 3031. Molecules 2023, 28, 5626. https://doi.org/10.3390/molecules28155626

AMA Style

Neamatallah T, El-Shitany N, Abbas A, Eid BG, Harakeh S, Ali S, Mousa S. Correction: Neamatallah et al. Nano Ellagic Acid Counteracts Cisplatin-Induced Upregulation in OAT1 and OAT3: A Possible Nephroprotection Mechanism. Molecules 2020, 25, 3031. Molecules. 2023; 28(15):5626. https://doi.org/10.3390/molecules28155626

Chicago/Turabian Style

Neamatallah, Thikryat, Nagla El-Shitany, Aymn Abbas, Basma G. Eid, Steve Harakeh, Soad Ali, and Shaker Mousa. 2023. "Correction: Neamatallah et al. Nano Ellagic Acid Counteracts Cisplatin-Induced Upregulation in OAT1 and OAT3: A Possible Nephroprotection Mechanism. Molecules 2020, 25, 3031" Molecules 28, no. 15: 5626. https://doi.org/10.3390/molecules28155626

Article Metrics

Back to TopTop